Niagen Bioscience/$NAGE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Niagen Bioscience
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Ticker
$NAGE
Sector
Health
Primary listing
Employees
104
Headquarters
Website
NAGE Metrics
BasicAdvanced
$768M
44.65
$0.22
2.13
-
Price and volume
Market cap
$768M
Beta
2.13
52-week high
$14.69
52-week low
$2.63
Average daily volume
1.3M
Financial strength
Current ratio
3.882
Quick ratio
3.161
Long term debt to equity
3.628
Total debt to equity
5.128
Profitability
EBITDA (TTM)
17.452
Gross margin (TTM)
63.62%
Net profit margin (TTM)
15.24%
Operating margin (TTM)
14.33%
Effective tax rate (TTM)
3.28%
Revenue per employee (TTM)
$1,120,000
Management effectiveness
Return on assets (TTM)
14.32%
Return on equity (TTM)
37.36%
Valuation
Price to earnings (TTM)
44.65
Price to revenue (TTM)
6.404
Price to book
11.94
Price to tangible book (TTM)
11.99
Price to free cash flow (TTM)
35.577
Free cash flow yield (TTM)
2.81%
Free cash flow per share (TTM)
0.27
Growth
Revenue change (TTM)
35.89%
Earnings per share change (TTM)
-816.96%
3-year revenue growth (CAGR)
18.98%
10-year revenue growth (CAGR)
19.40%
3-year earnings per share growth (CAGR)
-19.63%
10-year earnings per share growth (CAGR)
8.76%
What the Analysts think about NAGE
Analyst ratings (Buy, Hold, Sell) for Niagen Bioscience stock.
NAGE Financial Performance
Revenues and expenses
NAGE Earnings Performance
Company profitability
NAGE News
AllArticlesVideos
Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference
Business Wire·5 days ago
Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
Business Wire·2 weeks ago
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Niagen Bioscience stock?
Niagen Bioscience (NAGE) has a market cap of $768M as of August 09, 2025.
What is the P/E ratio for Niagen Bioscience stock?
The price to earnings (P/E) ratio for Niagen Bioscience (NAGE) stock is 44.65 as of August 09, 2025.
Does Niagen Bioscience stock pay dividends?
No, Niagen Bioscience (NAGE) stock does not pay dividends to its shareholders as of August 09, 2025.
When is the next Niagen Bioscience dividend payment date?
Niagen Bioscience (NAGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Niagen Bioscience?
Niagen Bioscience (NAGE) has a beta rating of 2.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.